Referred to the Committee on Ways and Means, and in addition to the Committees on Energy and Commerce, Agriculture, Natural Resources, Financial Services, Science, Space, and Tech…
This bill would repeal Public Law 117–169 (the Inflation Reduction Act of 2022) in its entirety and rescind unobligated balances of any amounts made available under that law. The text is a straightforward repeal and rescission instruction without specifying replacement provisions, transition rules, or schedules for unwinding individual programs.
Progressives emphasize climate and drug-cost rollbacks as main harms.
Relative to its intended legislative type, this bill is a straightforward, narrowly drafted repeal: it clearly identifies the statute to be repealed and rescinds unobligated balances, but it lacks explanatory findings, transitional rules, implementation guidance, fiscal analysis, and mechanisms for handling edge cases or accountability.
This bill would repeal Public Law 117–169 (the Inflation Reduction Act of 2022) in its entirety and rescind unobligated balances of any amounts made available under that law.
The text is a straightforward repeal and rescission instruction without specifying replacement provisions, transition rules, or schedules for unwinding individual programs.
High-policy impact, partisan target, no compromise features, and significant Senate hurdles make enactment unlikely based on text alone.
Relative to its intended legislative type, this bill is a straightforward, narrowly drafted repeal: it clearly identifies the statute to be repealed and rescinds unobligated balances, but it lacks explanatory findings, transitional rules, implementation guidance, fiscal analysis, and mechanisms for handling edge cases or accountability.
Progressives emphasize climate and drug-cost rollbacks as main harms.
These are examples from the analysis, not a ranked list of the most-affected groups.
Progressives emphasize climate and drug-cost rollbacks as main harms.
Strongly opposed.
They would view repeal as removing major climate, clean energy, and consumer health provisions created by the 2022 law.
They would see the rescission as cutting funds for programs aimed at emissions reductions, clean-energy jobs, and prescription drug cost relief.
Mixed and pragmatic.
They would weigh fiscal effects, implementation complexity, and political consequences.
Concerned about legal and contractual complications from an across-the-board repeal and the effects on energy markets, healthcare costs, and federal budgets.
Strongly supportive.
They would view repeal as rolling back a major Democratic-era package of spending, tax credits, and regulatory incentives.
They would emphasize fiscal savings, smaller federal role, and removal of what they see as market-distorting subsidies.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
High-policy impact, partisan target, no compromise features, and significant Senate hurdles make enactment unlikely based on text alone.
The bill has not accumulated any surfaced votes yet.
Progressives emphasize climate and drug-cost rollbacks as main harms.
High-policy impact, partisan target, no compromise features, and significant Senate hurdles make enactment unlikely based on text alone.
Relative to its intended legislative type, this bill is a straightforward, narrowly drafted repeal: it clearly identifies the statute to be repealed and rescinds unobligated balances, but it lacks explanatory findings,…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.